TAK-279

DRUG12 trials

Sponsors

Takeda

Conditions

Crohn's DiseaseErythrodermic PsoriasisGeneralized Pustular PsoriasisHealthy VolunteersHepatic ImpairmentPlaque PsoriasisRenal ImpairmentUlcerative Colitis

Phase 1

A Study of TAK-279 in Adults With or Without Liver Damage

CompletedNCT05976321

TakedaHealthy Volunteers, Hepatic Impairment

Start: 2023-09-22End: 2024-04-15Updated: 2024-08-29

A Study of TAK-279 in Adults With or Without Kidney Problems

CompletedNCT05992155

TakedaHealthy Volunteers, Renal Impairment

Start: 2023-09-27End: 2024-05-28Updated: 2024-06-27

A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults

CompletedNCT05995249

TakedaHealthy Volunteers

Start: 2023-08-11End: 2023-12-31Updated: 2024-02-06

A Study of TAK-279 in Healthy Chinese Adults

CompletedNCT06111547

TakedaHealthy Volunteers

Start: 2024-06-24End: 2024-08-04Updated: 2024-08-07

A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements

CompletedNCT06258265

TakedaHealthy Volunteers

Start: 2024-04-29End: 2024-07-09Updated: 2024-07-11

A Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults

CompletedNCT06290050

TakedaHealthy Volunteers

Start: 2024-03-29End: 2024-05-16Updated: 2024-05-23

Phase 2

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

RecruitingNCT06233461

TakedaCrohn's Disease

Start: 2024-03-05End: 2027-07-23Target: 268Updated: 2026-08-27

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Active, not recruitingNCT06254950

TakedaUlcerative Colitis

Start: 2024-03-29End: 2027-08-04Updated: 2026-08-17

Phase 3

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

CompletedNCT06088043

TakedaPlaque Psoriasis

Start: 2023-11-06End: 2025-10-22Updated: 2025-10-24

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

CompletedNCT06108544

TakedaPlaque Psoriasis

Start: 2023-11-06End: 2025-11-07Updated: 2025-11-20

A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

CompletedNCT06323356

TakedaErythrodermic Psoriasis, Generalized Pustular Psoriasis

Start: 2024-03-19End: 2026-07-10Updated: 2026-07-30

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Active, not recruitingNCT06550076

TakedaPlaque Psoriasis

Start: 2024-09-04End: 2029-08-05Updated: 2026-06-02

Related Papers

Zasocitinib (TAK-279), a Selective, Oral TYK2 Inhibitor, Reduces Body Surface Area Involvement in a Phase 2b Trial in Moderate-to-Severe Plaque Psoriasis

SKIN The Journal of Cutaneous Medicine2024-11-18

Evaluation of Changes in Laboratory Parameters from a Phase 2b Trial of Zasocitinib (TAK-279), an Oral, Selective TYK2 Inhibitor, in Patients with Moderate-to-Severe Plaque Psoriasis

SKIN The Journal of Cutaneous Medicine2024-11-18

Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis

JAMA Dermatology2024-08-2128 citations